R
Renta Hutabarat
Researcher at Alnylam Pharmaceuticals
Publications - 28
Citations - 4442
Renta Hutabarat is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: RNAi Therapeutics & Gene silencing. The author has an hindex of 13, co-authored 27 publications receiving 3741 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Teresa Coelho,David H. Adams,Ana Martins da Silva,Pierre Lozeron,Philip N. Hawkins,Timothy Mant,Javier Perez,Joseph Chiesa,Steve Warrington,Elizabeth Tranter,Malathy Munisamy,Rick Falzone,Jamie Harrop,Jeffrey Cehelsky,Brian Bettencourt,Mary Geissler,James Butler,Alfica Sehgal,Rachel Meyers,Qingmin Chen,Todd Borland,Renta Hutabarat,Valerie A. Clausen,Rene Alvarez,Kevin Fitzgerald,Christina Gamba-Vitalo,Saraswathy V. Nochur,Akshay Vaishnaw,Dinah W.Y. Sah,Jared Gollob,Ole B. Suhr +30 more
TL;DR: A therapeutic approach mediated by RNA interference (RNAi) could reduce the production of transthyretin in peripheral nerves and the heart as mentioned in this paper, which is caused by the deposition of hepatocyte-derived tranthymretin amyloid in peripheral nerve and heart.
Journal ArticleDOI
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair,Jennifer L. S. Willoughby,Amy Chan,Klaus Charisse,Md. Rowshon Alam,Qianfan Wang,Menno Hoekstra,Pachamuthu Kandasamy,Alexander V Kel'in,Stuart Milstein,Nate Taneja,Jonathan O'Shea,Sarfraz Shaikh,Ligang Zhang,Ronald J. van der Sluis,Michael E. Jung,Akin Akinc,Renta Hutabarat,Satya Kuchimanchi,Kevin Fitzgerald,Tracy Zimmermann,Theo J.C. Van Berkel,Martin Maier,Kallanthottathil G. Rajeev,Muthiah Manoharan +24 more
TL;DR: The optimally chemically modified siRNA-GalNAc conjugates are hepatotropic and long-acting and have the potential to treat a wide range of diseases involving liver-expressed genes.
Journal ArticleDOI
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero,Geoffrey I. Shapiro,Patricia LoRusso,Andrés Cervantes,Gary K. Schwartz,Glen J. Weiss,Luis Paz-Ares,Daniel C. Cho,Jeffrey R. Infante,Maria Alsina,Mrinal M. Gounder,Rick Falzone,Jamie Harrop,Amy C. Seila White,Ivanka Toudjarska,David Bumcrot,Rachel Meyers,Gregory Hinkle,Nenad Svrzikapa,Renta Hutabarat,Valerie A. Clausen,Jeffrey Cehelsky,Saraswathy V. Nochur,Christina Gamba-Vitalo,Akshay Vaishnaw,Dinah W.Y. Sah,Jared Gollob,Howard A. Burris +27 more
TL;DR: Safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel LNP-formulated RNAi therapeutic in patients with cancer are shown, providing proof-of-concept for RNAi therapeutics in humans and the basis for further development in cancer.
Journal ArticleDOI
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald,Maria Frank-Kamenetsky,Svetlana Shulga-Morskaya,Abigail Liebow,Brian Bettencourt,Jessica E. Sutherland,Renta Hutabarat,Valerie A. Clausen,Verena Karsten,Jeffrey Cehelsky,Saraswathy V. Nochur,Victor Kotelianski,Jay D. Horton,Timothy Mant,Joseph Chiesa,JM Ritter,Malathy Munisamy,Akshay Vaishnaw,Jared Gollob,Amy Simon +19 more
TL;DR: The results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol.
Journal ArticleDOI
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin Maier,Muthusamy Jayaraman,Shigeo Matsuda,Ju Liu,Scott A Barros,William Querbes,Ying K. Tam,Steven M. Ansell,Varun Kumar,June Qin,Xuemei Zhang,Qianfan Wang,Sue Panesar,Renta Hutabarat,Mary Carioto,Julia Hettinger,Pachamuthu Kandasamy,David Butler,Kallanthottathil G. Rajeev,Bo Pang,Klaus Charisse,Kevin Fitzgerald,Barbara L. Mui,Xinyao Du,Pieter R. Cullis,Thomas D. Madden,Michael J. Hope,Muthiah Manoharan,Akin Akinc +28 more
TL;DR: The aim of this work was to further advance the LNP platform through the development of novel, next-generation lipids that combine the excellent potency of the most advanced lipids currently available with biodegradable functionality.